Literature DB >> 21212403

Carotid intima-media thickness in psoriatic arthritis: differences between tumor necrosis factor-α blockers and traditional disease-modifying antirheumatic drugs.

Matteo Nicola Dario Di Minno1, Salvatore Iervolino, Rosario Peluso, Raffaele Scarpa, Giovanni Di Minno.   

Abstract

OBJECTIVE: Subjects with psoriatic arthritis (PsA) have an abnormally high prevalence of vascular risk factors (VRFs) and are predisposed to vascular mortality. Tumor necrosis factor (TNF)-α, a major determinant of inflammation, is involved in atherosclerosis. Ultrasonographic carotid intima-media thickness (C-IMT) evaluation allows for subclinical atherosclerosis detection. METHODS AND
RESULTS: Two hundred twenty-four PsA patients (120 on TNF-α blockers and 104 on traditional disease-modifying antirheumatic drugs [DMARDs]) underwent a C-IMT ultrasound assessment. As many as 305 matched subjects without any inflammatory/rheumatologic disease served as controls. The C-IMT of PsA subjects without VRFs was higher (P<0.0001) than that of controls, the C-IMT of PsA subjects with ≥1 VRF(s) was lower (P<0.0001) than that of controls, and the C-IMT was lower (P<0.0001) in those on TNF-α blockers than in those on DMARDs. Carotid plaques were detected in 15.8% of those on TNF-α blockers and in 40.4% of those on DMARDs (P<0.0001). Treatment duration inversely (β=-0.317, P<0.0001) predicted C-IMT in PsA subjects on TNF-α blockers but not in those on DMARDs (P=0.313).
CONCLUSIONS: Among PsA individuals, the C-IMT is higher in subjects on DMARDs than in those on TNF-α blockers. The reduction of inflammation may hamper the cascade that causes the raised vascular risk in PsA patients.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21212403     DOI: 10.1161/ATVBAHA.110.214585

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  32 in total

1.  Investigation of subclinical atherosclerosis in psoriatic arthritis patients with minimal disease activity.

Authors:  Baris Yilmazer; Tayfun Sahin; Berrin Öztaş Unlu; Hale Maral Kir; Ayse Cefle
Journal:  Rheumatol Int       Date:  2015-02-11       Impact factor: 2.631

2.  The impact of concomitant diffuse idiopathic skeletal hyperostosis on the achievement of minimal disease activity in subjects with psoriatic arthritis.

Authors:  Nicola Pappone; Matteo Nicola Dario Di Minno; Salvatore Iervolino; Roberta Lupoli; Reuven Mader; Carmela Zincarelli; Rosario Peluso
Journal:  Rheumatol Int       Date:  2015-06-06       Impact factor: 2.631

3.  Association between small dense LDL and sub-clinical atherosclerosis in patients with psoriatic arthritis.

Authors:  Marco Gentile; Rosario Peluso; Matteo Nicola Dario Di Minno; Luisa Costa; Francesco Caso; Biagio de Simone; Gabriella Iannuzzo; Raffaele Scarpa; Paolo Rubba
Journal:  Clin Rheumatol       Date:  2016-07-13       Impact factor: 2.980

Review 4.  Making the next steps in psoriatic arthritis management: current status and future directions.

Authors:  Diviya Sritheran; Ying Ying Leung
Journal:  Ther Adv Musculoskelet Dis       Date:  2015-10       Impact factor: 5.346

5.  Assessing joint involvement in haemophilia by clinical rheumatologic scores. A pilot study on similarities with subjects with psoriatic arthritis.

Authors:  Matteo Nicola Dario Di Minno; Salvatore Iervolino; Rosario Peluso; Antonio del Puente; Anna Russolillo; Antonio Coppola; Carlo Ruosi; Anna Guida; Raffaele Scarpa; Giovanni Di Minno
Journal:  Clin Rheumatol       Date:  2011-02-16       Impact factor: 2.980

Review 6.  Biological therapies for spondyloarthritis.

Authors:  Vincenzo Bruner; Mariangela Atteno; Angelo Spanò; Raffaele Scarpa; Rosario Peluso
Journal:  Ther Adv Musculoskelet Dis       Date:  2014-06       Impact factor: 5.346

Review 7.  Pharmacological treatment of spondyloarthritis: exploring the effectiveness of nonsteroidal anti-inflammatory drugs, traditional disease-modifying antirheumatic drugs and biological therapies.

Authors:  Francesco Caso; Luisa Costa; Antonio Del Puente; Matteo Nicola Dario Di Minno; Gelsy Lupoli; Raffaele Scarpa; Rosario Peluso
Journal:  Ther Adv Chronic Dis       Date:  2015-11       Impact factor: 5.091

Review 8.  Do anti-tumour necrosis factor-α biologics affect subclinical measures of atherosclerosis and arteriosclerosis? A systematic review.

Authors:  Laurence Knowles; Nida Nadeem; Philip J Chowienczyk
Journal:  Br J Clin Pharmacol       Date:  2020-03-08       Impact factor: 4.335

9.  Impact of hypertension on vascular remodeling in patients with psoriatic arthritis.

Authors:  M Puato; R Ramonda; A Doria; M Rattazzi; E Faggin; G Balbi; M Zanon; M Zanardo; C Tirrito; M Lorenzin; V Modesti; M Plebani; M Zaninotto; L Punzi; P Pauletto
Journal:  J Hum Hypertens       Date:  2013-07-11       Impact factor: 3.012

10.  Endothelial Pannexin 1 Channels Control Inflammation by Regulating Intracellular Calcium.

Authors:  Yang Yang; Leon J Delalio; Angela K Best; Edgar Macal; Jenna Milstein; Iona Donnelly; Ashley M Miller; Martin McBride; Xiaohong Shu; Michael Koval; Brant E Isakson; Scott R Johnstone
Journal:  J Immunol       Date:  2020-04-20       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.